LUCD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lucid Diagnostics Inc (LUCD) does not present a strong buy opportunity for a beginner investor with a long-term strategy at this time. While the company has shown revenue growth and received a positive analyst rating, its financial performance remains weak with negative net income, declining EPS, and gross margin. Additionally, there are no significant trading trends, news catalysts, or proprietary trading signals to support an immediate buy decision. The technical indicators are neutral to slightly bullish, but they do not provide enough conviction for a strong entry point.
The MACD is positive and contracting, indicating a slight bullish momentum. RSI is neutral at 51.109, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and key support and resistance levels are at S1: 1.127 and R1: 1.383. However, the pre-market price of 1.235 is below the pivot level of 1.255, indicating potential resistance ahead.
Analyst Edward Woo raised the price target to $9, citing high growth potential and Medicare coverage starting. Revenue increased by 25.65% YoY in Q4 2025.
Net income remains negative (-$16.27M), EPS dropped by 40% YoY, and gross margin declined significantly (-65.19% YoY). No recent news or significant trading trends from hedge funds or insiders. Congress trading data is also unavailable.
In Q4 2025, revenue increased by 25.65% YoY to $1.504M, but net income remains negative at -$16.27M. EPS dropped to -0.12 (-40% YoY), and gross margin fell to -30.65% (-65.19% YoY).
Ascendiant analyst Edward Woo raised the price target to $9 from $8.25 and maintained a Buy rating, citing high growth potential and Medicare coverage as key drivers.
